Biostax Stock Price, News & Analysis

Biostax Corp., formerly known as Immune Therapeutics, is a specialty pharmaceutical company dedicated to producing, distributing, and marketing patented therapies that activate and regulate the immune system to combat severe, life-threatening diseases. The company's technology platform is centered on two cutting-edge immunotherapies, low-dose naltrexone (LDN) and methionine-enkephalin (MENK), developed over decades at prestigious institutions such as Penn State University, University of Chicago, State University of New York, and UCSF Multiple Sclerosis Center.

In 2023, Biostax finalized the transfer of three Investigational New Drug Applications (INDs) for JKB-122, a TLR4 antagonist targeting autoimmune and inflammatory conditions like Non-Alcoholic Fatty Liver Disease, Autoimmune Hepatitis, and Non-Alcoholic Steatohepatitis. The company's collaboration with Immgenuity, Inc. aims to achieve HIV remission by combining IMTV014 with Biostax's Lodonal™ and JKB-122, highlighting their dedication to innovative therapies addressing unmet medical needs.

Through a diversified product pipeline and a hub-and-spoke business model, Biostax is committed to developing therapies that restore immune balance, provide disease remission, and improve the quality of life for patients with autoimmune, inflammatory, and infectious diseases.